 |
|
|
|
 |
|
|
 Contact |  Print version |  Send article |  RSS feed
Isotechnika receives notice of allowance for mTOR inhibitor, TAFA9324 Nov 2006 -
Isotechnika Inc. announced the Company has received a Notice of Allowance from the United States Patent and Trademark Office based on U.S. Patent Application Serial No. 10/845,747 for TAFA93, including both composition of matter and methods of use claims.
TAFA93, a pro-drug of rapamycin, is a novel small molecule mTOR inhibitor, which is a class of drugs currently used in combination with calcineurin inhibitors to prevent organ rejection following transplantation. According to the company, this class of drugs, in addition to transplantation, has potential for use in stent technology, autoimmune disease and oncology.
Additional information
Isotechnika Inc.
Edmonton, Alberta, Canada
Company
News
|
|
|
|
|
|
Top